Will the AI Act Break European Medtech? Inside the MDR/IVDR Revision

MedTech Europe's position paper outlines a critical juncture for medical device regulation in the EU. We unpack their proposed amendments to the MDR and IVDR, focusing on how AI should be regulated, the fight over cybersecurity reporting, and why one in three manufacturers is deprioritising the EU for product launches.

Key points

• One in three manufacturers is currently deprioritising the European Union for first regulatory approvals due to administrative burden and costs.
• MedTech Europe strongly supports embedding AI Act requirements into the MDR and IVDR to allow for a single conformity assessment, preventing dual-regulatory overlap.
• They propose a 12-month deadline for the European Commission to adopt delegated acts integrating high-risk AI requirements into existing safety frameworks.
• The position paper calls for structurally separating cybersecurity vulnerability reporting from traditional patient safety vigilance to avoid false alarms and regulatory confusion.
• For in vitro diagnostics, MedTech Europe wants the orphan device threshold changed from 1 in 12,000 to 5 in 10,000 to align with the established rare disease definition.
• The industry opposes a proposed regulatory shift that would make devices reusable by default, arguing that single-use engineering is fundamental to patient safety.

Source: MDR/IVDR Revision: A regulatory system at a crossroads - MedTech Europe, 2026

This spot is available. Reach clinicians, health-system leaders and medtech and pharma teams following AI in medicine. Sponsor the show

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/will-the-ai-act-break-european-medtech-inside-the-mdr-ivdr-revision-5f21c6